"10.1371_journal.pone.0053463","plos one","2013-01-30T00:00:00Z","Luk H Vandenberghe; Peter Bell; Albert M Maguire; Ru Xiao; Tim B Hopkins; Rebecca Grant; Jean Bennett; James M Wilson","Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: LHV JB JMW. Performed the experiments: LHV PB AMM RX TBH RG. Analyzed the data: LHV PB AMM JB JMW. Contributed reagents/materials/analysis tools: JMW. Wrote the paper: LHV PB JB JMW.","The authors have the following interests. LHV is co-inventor on patents describing several of the AAV serotypes described in this manuscript as well as related technologies. These patents have been licensed to various pharmaceutical and biotechnological enterprises, and further details are available on request. LHV and JB are co-founders of GenSight Biologics which pursues ocular gene therapy approaches using AAV. JB and AMM are co-inventors of a patent for a method to treat or slow the development of blindness (US patent 424/93.2), but both waived any financial interest in this technology in 2002. JMW is a consultant to ReGenX Holdings, and is a founder of, holds equity in, and receives a grant from affiliates of ReGenX Holdings; in addition, he is an inventor on patents licensed to various biopharmaceutical companies, including affiliates of ReGenX Holdings. Further details are available on request. This study was partly supported by GlaxoSmithKline. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","01","Luk H Vandenberghe","LHV",8,TRUE,3,6,5,4,TRUE,TRUE,FALSE,0,NA,FALSE
